Home›Cardiology› High-risk APOL1 genotypes more than double odds of lupus nephritis ESRD
High-risk APOL1 genotypes more than double odds of lupus nephritis ESRDHigh Risk APOL1 Genotypes Linked to Kidney Damage in Lupus
Frontiers in MedicinePublished August 20, 2026Study authors: Silvia E. Aldana-Pérez, Alex Dominguez-Vargas, Gustavo Aroca-Martinez, Ana Moreno-Woo, Luis Fang, Gl…DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider APOL1 genotype as a risk factor for ESRD in lupus nephritis, but interpret cautiously.
This meta-analysis pooled data from 1,885 patients of African ancestry with systemic lupus erythematosus (SLE) to assess the association between high-risk APOL1 genotypes and renal outcomes. The primary outcome was lupus nephritis (LN)-associated end-stage renal disease (ESRD), with chronic kidney disease as a secondary outcome. The analysis compared patients with high-risk APOL1 genotypes to those with low-risk genotypes.
The main finding was a significantly increased odds of LN-associated ESRD in patients with high-risk APOL1 genotypes (OR 2.66, 95% CI 1.63–4.32; p=0.008). This effect was observed in an observational meta-analysis, and the authors note that causality is not established. Heterogeneity for the primary outcome was low (I² = 9.8%).
The authors suggest that APOL1 is a clinically relevant genetic modifier of renal prognosis and may serve as a tool for risk stratification and precision medicine in lupus nephritis. However, they caution against overstating its role in these applications.
Limitations include heterogeneous reporting of chronic kidney disease outcomes across studies. The meta-analysis did not report follow-up duration, adverse events, or funding details.
For clinicians, these findings highlight the potential importance of APOL1 genotype in assessing renal risk in SLE patients of African ancestry, but further research is needed to clarify its clinical utility.
How this fits prior evidence
This meta-analysis extends prior genetic findings in SLE by identifying APOL1 as a specific risk factor for lupus nephritis progression to ESRD. It complements the earlier meta-analysis that identified 101 genetic risk loci for SLE, adding a clinically relevant gene with a large effect size (OR 2.66). The finding also aligns with the recognition of mucocutaneous manifestations as diagnostic indicators, as both emphasize early risk identification. However, unlike CAR T-cell therapy which offers a treatment approach, this study focuses on risk stratification, addressing a gap in prognostic tools for SLE patients of African ancestry.
Researchers analyzed data from 1,885 patients of African ancestry who have systemic lupus erythematosus (SLE). The study looked specifically at how certain genetic markers, known as high-risk APOL1 genotypes, relate to the development of end-stage renal disease (ESRD) in those with lupus nephritis.
The results showed that people with these high-risk APOL1 genotypes had significantly higher odds of developing kidney failure compared to those with low-risk genotypes. Specifically, the data indicated a much higher likelihood of severe kidney damage for patients carrying the high-risk markers.
While this finding suggests that the APOL1 gene could help doctors identify who might need closer monitoring, it is important to note that this was an observational study. This means the research shows a link between genes and kidney health but does not prove that the gene causes the disease. Because of these complexities, patients should talk to their doctors about how genetic factors might affect their specific treatment plan.
What this means for you:
High-risk APOL1 genotypes are linked to higher rates of kidney failure in patients with lupus nephritis.
Common questions
What is the link between the APOL1 gene and lupus?
The study found that patients of African ancestry with systemic lupus erythematosus (SLE) who had high-risk APOL1 genotypes were more likely to develop end-stage renal disease. This suggests the gene may act as a marker for kidney health in these patients.
Who is most affected by this genetic finding?
The study specifically looked at 1,885 patients of African ancestry with systemic lupus erythematosus (SLE). The findings focus on those who also have lupus nephritis, which involves inflammation of the kidneys.
Does this mean the APOL1 gene causes kidney failure?
The study shows a link between high-risk APOL1 genotypes and increased odds of end-stage renal disease. However, because it was an observational study, it does not prove that the gene directly causes the condition.
Systemic lupus erythematosus (SLE) is characterized by a prominent interferon signature that upregulates apolipoprotein L1 (APOL1) expression. High-risk APOL1 genotypes have been associated with end-stage renal disease (ESRD) as a complication of lupus nephritis (LN); however, the strength and consistency of this association remain heterogeneous across studies.
We conducted a systematic review and meta-analysis of observational studies to evaluate the association between APOL1 genotypes and the odds of LN-associated kidney failure among patients with SLE. A systematic search of PubMed, Scopus, and Web of Science identified eligible observational studies, and pooled odds ratios with 95% confidence intervals were estimated using random-effects models. Between-study heterogeneity and publication bias were assessed using standard methods.
Four observational studies comprising a total of 1,885 patients of African ancestry were included. Of these, 321 carried high-risk APOL1 genotypes and 1,564 carried low-risk genotypes. High-risk APOL1 genotypes were associated with significantly increased odds of LN-associated ESRD compared with low-risk genotypes (OR 2.66; 95% CI 1.63–4.32; p = 0.008), with low heterogeneity (I2 = 9.8%). Chronic kidney disease outcomes were reported heterogeneously and were summarized descriptively.
High-risk APOL1 genotypes are associated with significantly increased pooled odds of LN-associated ESRD among patients with SLE. These findings demonstrate that APOL1 is a clinically relevant genetic modifier of renal prognosis, supporting its potential role as a tool for risk stratification and precision medicine approaches in LN.
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024587943, identifier PROSPERO (CRD42024587943).
